Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
Circulating tumor DNA
Circulating tumor cells
Exosomes
Liquid biopsy
Multi-omic approach
Pancreatic cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
10 Jun 2024
10 Jun 2024
Historique:
received:
06
05
2024
accepted:
31
05
2024
medline:
10
6
2024
pubmed:
10
6
2024
entrez:
9
6
2024
Statut:
epublish
Résumé
Pancreatic cancer, predominantly characterized by ductal adenocarcinoma (PDAC) accounts for 90% of cases and is the fourth leading cause of cancer-related deaths globally. Its incidence is notably increasing. This poor prognosis is primarily due to late-stage diagnosis (approximately 70% to 80% of patients are diagnosed at an advanced stage), aggressive tumor biology, and low sensitivity to chemotherapy. Consequently, it is crucial to identify and develop a simple, feasible and reproducible blood-based signature (i.e., combination of biomarkers) for early detection of PDAC. The PANLIPSY study is a multi-center, non-interventional prospective clinical trial designed to achieve early detection of PDAC with high specificity and sensitivity, using a combinatorial approach in blood samples. These samples are collected from patients with resectable, borderline or locally advanced, and metastatic stage PDAC within the framework of the French Biological and Clinical Database for PDAC cohort (BACAP 2). All partners of the BACAP consortium are eligible to participate. The study will include 215 PDAC patients, plus 25 patients with benign pancreatic conditions from the PAncreatic Disease Cohort of TOuLouse (PACTOL) cohort, and 115 healthy controls, totaling 355 individuals. Circulating biomarkers will be collected in a total volume of 50 mL of blood, divided into one CellSave tube (10 mL), two CELL-FREE DNA BCT® preservative tubes (18 mL), and five EDTA tubes (22 mL in total). Samples preparation will adhere to the guidelines of the European Liquid Biopsy Society (ELBS). A unique feature of the study is the AI-based comparison of these complementary liquid biopsy biomarkers. Main end-points: i) to define a liquid biopsy signature that includes the most relevant circulating biomarkers, ii) to validate the multi-marker panel in an independent cohort of healthy controls and patients, with resectable PDAC, and iii) to establish a unique liquid biopsy biobank for PDAC study. The PANLIPSY study is a unique prospective non-interventional clinical trial that brings together liquid biopsy experts. The aim is to develop a biological signature for the early detection of PDAC based on AI-assisted detection of circulating biomarkers in blood samples (CTCs, ctDNA, EVs, circulating immune system, circulating cell-free nucleosomes, proteins, and microbiota). ClinicalTrials.gov Identifier: NCT06128343 / NCT05824403. Registration dates: June 8,2023 and April 21, 2023.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic cancer, predominantly characterized by ductal adenocarcinoma (PDAC) accounts for 90% of cases and is the fourth leading cause of cancer-related deaths globally. Its incidence is notably increasing. This poor prognosis is primarily due to late-stage diagnosis (approximately 70% to 80% of patients are diagnosed at an advanced stage), aggressive tumor biology, and low sensitivity to chemotherapy. Consequently, it is crucial to identify and develop a simple, feasible and reproducible blood-based signature (i.e., combination of biomarkers) for early detection of PDAC.
METHODS
METHODS
The PANLIPSY study is a multi-center, non-interventional prospective clinical trial designed to achieve early detection of PDAC with high specificity and sensitivity, using a combinatorial approach in blood samples. These samples are collected from patients with resectable, borderline or locally advanced, and metastatic stage PDAC within the framework of the French Biological and Clinical Database for PDAC cohort (BACAP 2). All partners of the BACAP consortium are eligible to participate. The study will include 215 PDAC patients, plus 25 patients with benign pancreatic conditions from the PAncreatic Disease Cohort of TOuLouse (PACTOL) cohort, and 115 healthy controls, totaling 355 individuals. Circulating biomarkers will be collected in a total volume of 50 mL of blood, divided into one CellSave tube (10 mL), two CELL-FREE DNA BCT® preservative tubes (18 mL), and five EDTA tubes (22 mL in total). Samples preparation will adhere to the guidelines of the European Liquid Biopsy Society (ELBS). A unique feature of the study is the AI-based comparison of these complementary liquid biopsy biomarkers. Main end-points: i) to define a liquid biopsy signature that includes the most relevant circulating biomarkers, ii) to validate the multi-marker panel in an independent cohort of healthy controls and patients, with resectable PDAC, and iii) to establish a unique liquid biopsy biobank for PDAC study.
DISCUSSION
CONCLUSIONS
The PANLIPSY study is a unique prospective non-interventional clinical trial that brings together liquid biopsy experts. The aim is to develop a biological signature for the early detection of PDAC based on AI-assisted detection of circulating biomarkers in blood samples (CTCs, ctDNA, EVs, circulating immune system, circulating cell-free nucleosomes, proteins, and microbiota).
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT06128343 / NCT05824403. Registration dates: June 8,2023 and April 21, 2023.
Identifiants
pubmed: 38853244
doi: 10.1186/s12885-024-12463-8
pii: 10.1186/s12885-024-12463-8
doi:
Substances chimiques
Biomarkers, Tumor
0
Banques de données
ClinicalTrials.gov
['NCT06128343', 'NCT05824403']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
709Informations de copyright
© 2024. The Author(s).
Références
Pereira SP, et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020;5(7):698–710.
doi: 10.1016/S2468-1253(19)30416-9
pubmed: 32135127
pmcid: 7380506
Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005;23(20):4524–31.
doi: 10.1200/JCO.2005.19.711
pubmed: 16002843
Conroy T, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(11):987–1002.
Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398–406.
doi: 10.1016/j.molmed.2010.07.001
pubmed: 20667783
Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858–73.
doi: 10.1158/2159-8290.CD-20-1311
pubmed: 33811121
Wu H, et al. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. BMC Med. 2022;20(1):458.
doi: 10.1186/s12916-022-02647-z
pubmed: 36434648
pmcid: 9701032
Nitschke C, et al. Peripheral and portal venous KRAS ctDNA detection as independent prognostic markers of early tumor recurrence in pancreatic ductal adenocarcinoma. Clin Chem. 2023;69(3):295–307.
doi: 10.1093/clinchem/hvac214
pubmed: 36644936
Duffy MJ, Diamandis EP, Crown J. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? Clin Chem Lab Med. 2021;59(8):1353–61.
doi: 10.1515/cclm-2021-0171
pubmed: 33856748
Pons-Belda OD, Fernandez-Uriarte A, Diamandis EP. Can circulating tumor DNA support a successful screening test for early cancer detection? The Grail paradigm. Diagnostics (Basel). 2021;11(12):2171.
doi: 10.3390/diagnostics11122171
pubmed: 34943407
Alix-Panabières C. The future of liquid biopsy. Nature. 2020;579(7800):S9.
doi: 10.1038/d41586-020-00844-5
pubmed: 32214259
Canivet C, et al. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. BMC Cancer. 2018;18(1):986.
doi: 10.1186/s12885-018-4906-4
pubmed: 30326968
pmcid: 6191891
Pietrasz D, et al. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Br J Cancer. 2022;126(3):440–8.
doi: 10.1038/s41416-021-01624-2
pubmed: 34811505
Garrigou S, et al. A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem. 2016;62(8):1129–39.
doi: 10.1373/clinchem.2015.253609
pubmed: 27251038
Huggett JF. The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020. Clin Chem. 2020;66(8):1012–29.
doi: 10.1093/clinchem/hvaa125
pubmed: 32746458
Holdenrieder S, et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res. 2014;34(5):2357–62.
pubmed: 24778043
Van den Ackerveken P, et al. Epigenetic profiles of elevated cell free circulating H3. 1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma. Sci Rep. 2023;13(1):16335.
doi: 10.1038/s41598-023-43520-0
pubmed: 37770512
pmcid: 10539380
Kramski M, et al. Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation. J Clin Microbiol. 2011;49(10):3691–3.
doi: 10.1128/JCM.01018-11
pubmed: 21813723
pmcid: 3187295
Buscail E, et al. High clinical value of liquid biopsy to detect circulating tumor cells and tumor exosomes in pancreatic ductal adenocarcinoma patients eligible for up-front surgery. Cancers. 2019;11(11):1656.
doi: 10.3390/cancers11111656
pubmed: 31717747
pmcid: 6895804
Cortés-Hernández LE, et al. Current applications and discoveries related to the membrane components of circulating tumor cells and extracellular vesicles. Cells. 2021;10(9):2221.
doi: 10.3390/cells10092221
pubmed: 34571870
pmcid: 8465935
Rifai N. Tietz Textbook of Laboratory Medicine-E-Book: Tietz Textbook of Laboratory Medicine-E-Book. England: Elsevier Health Sciences; 2022.